Skip to main content

European Hidradenitis Suppurativa Foundation (EHSF), 2024

  1. Congress Materials
FILTER
Clear all
Content type:
Poster European Hidradenitis Suppurativa Foundation (EHSF), 2024
Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa
Ingram R. John, Sayed Christopher, Jacobs-Lee Rickie, et al.
Poster
Poster European Hidradenitis Suppurativa Foundation (EHSF), 2024
Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48
Kirby S. Joslyn, Daveluy Steven, Pinter Andreas, et al.
Poster
Poster European Hidradenitis Suppurativa Foundation (EHSF), 2024
Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II
Hessel H. van der Zee, Kirby Brian, Bechara G. Falk, et al.
Poster
Poster European Hidradenitis Suppurativa Foundation (EHSF), 2024
Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II
Tzellos Thrasyvoulos, Alavi Afsaneh, Kyrgidis Athanassios, et al.
Poster
Poster European Hidradenitis Suppurativa Foundation (EHSF), 2024
Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II
Kimball B. Alexa, Shi Y Vivian, Porter Martina, et al.
Poster
Poster European Hidradenitis Suppurativa Foundation (EHSF), 2024
IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials
Zouboulis C. Christos, Kirby S. Joslyn, Tzellos Thrasyvoulos, et al.
Poster